Selank: A Synthetic Tuftsin Analogue Studied for Anxiolytic Activity

Research summary. Selank is a synthetic heptapeptide developed at the Russian Institute of Molecular Genetics, structurally derived from the immunomodulatory tetrapeptide tuftsin with an added Pro-Gly-Pro tripeptide sequence to extend metabolic stability. The added C-terminal sequence prolongs plasma half-life from minutes to hours, enabling intranasal administration in research settings. Selank is studied for its reported anxiolytic, nootropic, and stress-modulation effects, with a published mechanism implicating GABAergic signalling, enkephalin metabolism, and BDNF expression. It is approved as a prescription anxiolytic in Russia and several CIS countries but is not approved in the United States or European Union.

Molecular profile

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular formula: C₃₃H₅₇N₁₁O₉
• Molecular weight: ~751.9 g/mol
• Class: Synthetic tuftsin analogue (heptapeptide)
• Synonyms: TP-7; tuftsin analog

Mechanism of action

Selank is reported to act via a multi-pathway profile rather than a single high-affinity receptor:

• Indirect GABAergic modulation. Rodent studies have reported that Selank modulates expression of multiple GABA-receptor-related genes in the brain, with described changes in GABA receptor affinity profiles. This is interpreted as the basis for the benzodiazepine-like anxiolytic effects reported in animal models.
• Inhibition of enkephalin degradation. Selank has been reported to inhibit enkephalinase activity, prolonging the half-life of endogenous enkephalins and providing an additional contribution to the reported anxiolytic effect.
• BDNF and monoamine effects. Reported effects on brain-derived neurotrophic factor expression and on monoamine neurotransmitter systems are described in the Russian research literature.
• Tuftsin-derived immunomodulation. Inherited from the parent peptide, Selank retains some immunomodulatory activity (effects on IL-6 and T-helper cells) characteristic of tuftsin.

The combined profile is positioned in the originating literature as benzodiazepine-like anxiolytic activity without the dependence and withdrawal liability of GABAA-receptor positive allosteric modulators.

Preclinical and clinical research highlights

Animal anxiety models. Rodent elevated-plus-maze and open-field studies have reported anxiolytic profiles comparable to benzodiazepines, with the added observation that Selank does not appear to produce tolerance or withdrawal-type endpoints in repeated-dosing studies.

GABA-system gene-expression effects. Cell- and tissue-level work has reported that of 84 GABA-signalling genes examined in rats, 7 are substantially modulated by Selank exposure with altered expression in 45 additional loci, consistent with a transcriptional contribution to its effects.

Generalised anxiety disorder clinical research. Russian clinical trials have reported Selank efficacy in generalised anxiety disorder, including in combination with benzodiazepine pharmacology where additive or synergistic effects have been described.

Nootropic and stress-resilience endpoints. Reported effects include improved attention and memory performance under stress, and reduction of stress-induced behavioural changes in rodent models.

Limitations of the evidence base

• The published Selank literature is concentrated almost entirely in Russian research groups, with limited independent Western replication.
• Mechanistic claims regarding direct gene-expression effects on GABA-receptor systems are not yet firmly established outside the originating programme.
• Western regulatory approval is absent; clinical evidence does not currently meet FDA or EMA standards for an anxiety indication.

Current research status

Selank is not approved by the FDA in the United States or by the EMA in Europe. It is approved as a prescription anxiolytic in Russia. Research-grade Selank is supplied for laboratory use only.

For research-supplier contexts, Selank is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Selank is a synthetic heptapeptide tuftsin analogue (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia for anxiolytic and nootropic research.
• Reported mechanisms include modulation of GABAergic gene expression, inhibition of enkephalin degradation, and effects on BDNF and monoamine systems.
• Animal-model and Russian clinical research have reported benzodiazepine-comparable anxiolytic activity without tolerance- or withdrawal-type endpoints.
• Selank is approved as a prescription anxiolytic in Russia but is not FDA- or EMA-approved.
• The published literature is concentrated in the originating Russian research programme; independent Western replication is limited.

References

1. Kost NV, Sokolov OY, Kolobov AA, Kampe-Nemm EA, Mikheeva IG, Andreeva LA, Myasoedov NF, Zozulya AA. Anxiolytic action of the peptide Selank. Bull Exp Biol Med. 2001;132(1):700–702.
2. Medvedev VE, Tereshchenko OY, Israelyan AY, Chobanu IK, Kost NV, Myasoedov NF. The optimization of pharmacotherapy of generalized anxiety disorder with the use of Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17–22.

---

This article is provided for educational and research purposes only. Selank is a research peptide and is not an approved drug or therapeutic agent in the United States or European Union. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.